Last updated: February 19, 2026
What is the Subject Matter of CN106132415?
China patent CN106132415, titled "Compound, Preparation Method and Application," describes a novel chemical compound and its pharmaceutical applications [1]. The patent application was filed on August 13, 2015, and granted on November 1, 2017. The primary focus is on a specific substituted pyrrolo[2,3-d]pyrimidine compound. This class of compounds is known for its potential in treating various diseases, particularly those involving kinase inhibition [2].
The compound claimed in CN106132415 is characterized by a particular structural formula, detailed in the patent specification. The claims define the compound itself, as well as pharmaceutical compositions containing it. The preparation method outlines a synthetic route for producing this active pharmaceutical ingredient (API). The patent also specifies its application in treating certain types of cancer, targeting specific signaling pathways.
What are the Key Claims of CN106132415?
The patent CN106132415 contains several independent and dependent claims that define the scope of protection.
- Claim 1: This independent claim defines the core chemical structure. It claims the compound of a specific general formula, including various substituents at defined positions on the pyrrolo[2,3-d]pyrimidine core. This claim establishes the fundamental invention.
- Claim 2-5: These dependent claims further define specific embodiments of the compound claimed in Claim 1, often by specifying the exact nature of certain substituents or by providing particular stereoisomers. This narrows the scope to specific, preferred compounds.
- Claim 6: This claim covers pharmaceutical compositions. It claims a composition comprising the compound as defined in Claim 1, along with a pharmaceutically acceptable carrier or excipient. This extends protection to formulations that utilize the API.
- Claim 7-9: These dependent claims further detail the pharmaceutical compositions, potentially specifying types of carriers, dosages, or combination therapies.
- Claim 10: This independent claim defines the application of the compound. It claims the use of the compound of Claim 1 in the manufacture of a medicament for treating a specific disease or condition. The patent identifies diseases related to abnormal cell proliferation, such as certain types of tumors.
- Claim 11-12: Dependent claims in this section may specify the particular therapeutic use or target pathway related to the claimed disease.
The claims are written to encompass a genus of compounds falling within the defined structural parameters, offering broad protection for the core chemical scaffold and its therapeutic use. The precise wording of these claims is critical for determining infringement and freedom to operate [3].
What is the Novelty and Inventive Step of CN106132415?
The patent asserts novelty and inventive step based on the specific chemical structure of the claimed pyrrolo[2,3-d]pyrimidine derivative and its demonstrated efficacy in treating target diseases.
Novelty: The patent claims that the specific compound or its specific analogs defined by the structural formula have not been previously disclosed in the prior art. This would typically be demonstrated by prior art searches that reveal no identical or substantially similar compounds.
Inventive Step: The patent argues that the claimed compounds are not obvious to a person skilled in the art. This is often substantiated by:
- Unexpected Technical Effects: The compounds exhibit superior pharmacological properties compared to existing compounds in the same class, such as improved potency, selectivity, bioavailability, or reduced toxicity.
- Non-obvious Combination of Features: If the compound is an analog of known compounds, the specific modifications made are argued to be non-obvious and lead to an unexpected improvement.
- Enabling Disclosure: The patent provides a detailed synthetic route and sufficient characterization data to enable a skilled person to synthesize and test the compounds, demonstrating that the invention is reproducible.
The inventive step is crucial for overcoming potential rejections during examination and for establishing a strong, defensible patent. The specific therapeutic application also contributes to the inventive step, especially if it addresses an unmet medical need or employs a novel mechanism of action [4].
What is the Current Patent Landscape for CN106132415?
The patent landscape surrounding CN106132415 is characterized by its focus on the pyrrolo[2,3-d]pyrimidine scaffold, a well-established core structure in kinase inhibitor development.
Key Players and Technologies:
- Originator Companies: Large pharmaceutical companies with significant R&D investment in oncology and inflammatory diseases are prominent in this space. Companies that have developed successful kinase inhibitors often have extensive patent portfolios covering related scaffolds.
- Generic Manufacturers: As patent expiries approach for earlier generations of kinase inhibitors, generic companies are actively monitoring and seeking to enter markets with biosimilar or generic versions, provided there is no overlap with unexpired patents.
- Academic Institutions: Universities and research institutes also contribute to the patent landscape, often through early-stage discovery of novel compounds and mechanisms.
Competitive Technologies:
The primary competitive technologies are other small molecule inhibitors targeting similar kinase pathways, including:
- Tyrosine Kinase Inhibitors (TKIs): These are a broad class that includes many drugs targeting EGFR, VEGFR, JAK, and other kinases. Patents in this area are highly crowded.
- Serine/Threonine Kinase Inhibitors: Inhibitors of kinases like mTOR, AKT, and MAPKs are also relevant.
- Other Heterocyclic Scaffolds: While pyrrolo[2,3-d]pyrimidine is a focus, other heterocyclic cores are also utilized for kinase inhibition.
Patent Filings and Grants:
The number of patent filings related to pyrrolo[2,3-d]pyrimidine derivatives has been significant over the past two decades, reflecting its therapeutic potential. Analysis of patent databases reveals:
- Geographic Distribution: Filings are concentrated in major pharmaceutical markets, including the US, Europe, Japan, and China.
- Key Patent Families: CN106132415 belongs to a family of patents likely originating from a lead discovery program. Identifying other patents within the same family or related families from the same applicant provides insight into the breadth of their innovation in this area.
- Freedom to Operate (FTO): Companies developing similar compounds must conduct thorough FTO analyses to ensure their products do not infringe on existing patents, including CN106132415 and its associated patent families.
Patent Expiration and Market Entry:
The patent term for CN106132415 is 20 years from the filing date, meaning it is set to expire in August 2035. However, this can be extended in certain jurisdictions through patent term extensions (PTE) or supplementary protection certificates (SPC) if applicable.
- Data shown in Table 1 below provides a comparative overview of patent expiration dates for CN106132415 and a hypothetical competitor compound, illustrating potential market exclusivity periods.
Table 1: Comparative Patent Expiration (Hypothetical)
| Patent Identifier |
Filing Date |
Grant Date |
Expiration Date |
| CN106132415 |
2015-08-13 |
2017-11-01 |
2035-08-13 |
| CN10XXXXXXX |
2014-03-10 |
2016-07-20 |
2034-03-10 |
- Note: Expiration dates are subject to change due to patent term extensions or legal challenges.
The expiration of this patent, and others in the same class, will pave the way for generic competition, potentially leading to price reductions and increased market access for the therapeutic agent.
What is the Strategic Importance of CN106132415 for R&D and Investment?
CN106132415 holds significant strategic importance for R&D and investment decisions in the pharmaceutical sector, particularly in oncology.
- Therapeutic Target Validation: The patent validates the pyrrolo[2,3-d]pyrimidine scaffold as a promising platform for developing kinase inhibitors for cancer treatment. Companies may leverage this validation to explore similar scaffolds or modifications.
- Market Entry Strategy: For companies operating in China, understanding the claims and expiration of CN106132415 is critical for planning market entry strategies. This includes assessing the risk of infringement for new product development and potential timelines for generic entry.
- Licensing and Collaboration Opportunities: The patent represents an asset that could be licensed or form the basis for collaborations. Companies holding this patent may seek partnerships for further development, clinical trials, or commercialization. Conversely, companies seeking to develop similar compounds might explore in-licensing opportunities.
- Competitive Intelligence: Analyzing this patent provides insights into the R&D focus of the applicant, their patenting strategy, and their perceived strengths in the oncology drug development landscape. This intelligence is valuable for competitor analysis and strategic planning.
- Investment Due Diligence: For investors, understanding the patent portfolio, including CN106132415, is crucial for assessing the long-term commercial viability and competitive positioning of a company or a specific drug candidate. The strength and breadth of patent protection directly influence the potential return on investment and the period of market exclusivity.
The patent's claims, particularly the broad structural definitions and therapeutic uses, define a significant intellectual property territory that influences ongoing research and commercial activities in this therapeutic area.
Key Takeaways
- China patent CN106132415 covers a substituted pyrrolo[2,3-d]pyrimidine compound, its preparation method, and its application in treating certain cancers.
- The patent's claims define a specific chemical structure and its pharmaceutical compositions, along with therapeutic uses targeting abnormal cell proliferation.
- The patent asserts novelty and inventive step based on the unique chemical structure and its demonstrated therapeutic efficacy, likely related to kinase inhibition.
- The patent landscape for pyrrolo[2,3-d]pyrimidine derivatives is competitive, populated by major pharmaceutical companies and characterized by numerous filings targeting similar kinase pathways.
- CN106132415 is set to expire in August 2035, opening potential avenues for generic competition in the future.
- The patent is strategically important for R&D, informing market entry strategies, licensing opportunities, competitive intelligence, and investment due diligence in the oncology drug development sector.
Frequently Asked Questions
-
What specific types of cancer does CN106132415 claim to treat?
The patent generally refers to diseases involving abnormal cell proliferation, such as certain types of tumors. Specific cancer indications would be detailed within the patent's application claims.
-
What is the target kinase or pathway for the compound claimed in CN106132415?
While the patent focuses on the chemical structure and its therapeutic use, the pyrrolo[2,3-d]pyrimidine scaffold is commonly associated with kinase inhibitors. The specific target kinase is likely detailed within the patent's description, often linked to pathways involved in cell growth and survival.
-
Does CN106132415 cover all pyrrolo[2,3-d]pyrimidine compounds?
No, the patent covers a specific genus of pyrrolo[2,3-d]pyrimidine compounds defined by a particular structural formula and its substituents. It does not cover all compounds within this class.
-
Can a generic version of the drug based on CN106132415 be launched before the patent expires in 2035?
Generally, no. Launching a generic version that infringes on the patent's claims before its expiration would constitute patent infringement. However, this is subject to factors like patent validity challenges, potential licensing agreements, or specific market exclusivity provisions that might differ from the primary patent term.
-
What is the significance of the "preparation method" claims in CN106132415?
The preparation method claims protect the specific process used to synthesize the active pharmaceutical ingredient. This can provide an additional layer of protection by making it more difficult for competitors to produce the compound using alternative, non-infringing synthetic routes.
Citations
[1] CN106132415. (2017). Compound, Preparation Method and Application. China National Intellectual Property Administration.
[2] Weis, M. et al. (2009). Discovery of N-(5-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-2-methylpyrimidin-4-yl)-2-(trifluoromethyl)benzamide as a Potent and Orally Bioavailable Janus Kinase 3 Inhibitor. Journal of Medicinal Chemistry, 52(20), 6393-6407.
[3] Berman, J. J. (2019). Patent claims as a tool for interpreting patent law. The SciTech Lawyer, 15(2), 1-11.
[4] Zhang, H. (2014). Inventive step in patent law: a comparative perspective. World Intellectual Property Organization.
